Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 13

Change from baseline in eGFR over the 24-week follow-up period in the CKD stage 3b subgroup.

Time	Treatment group	Control group	Effect	F value	value
Pretreatment (ml/min/1.73 m^2)	36.53 ± 4.36	37.53 ± 4.34	Time effect	3.4	0.0043
Week 4 (ml/min/1.73 m^2)	38.76 ± 6.68	38.22 ± 7.50	Difference between groups	23.68	<0.0001
Week 8 (ml/min/1.73 m^2)	41.49 ± 9.64	38.16 ± 8.49
Week 12 (ml/min/1.73 m^2)	41.80 ± 8.85	38.73 ± 8.65
Week 16 (ml/min/1.73 m^2)	43.01 ± 9.40	37.55 ± 7.81
Week 20 (ml/min/1.73 m^2)	43.23 ± 9.54	37.11 ± 7.42
Week 24 (ml/min/1.73 m^2)	43.37 ± 9.66	37.53 ± 8.23